Comments on: Avineuro Pharmaceuticals, Inc. reports positive Phase 2a clinical proof of concept trial results on AVN-211, potent small molecule for treatment of schizophrenia.

Comments on: Avineuro Pharmaceuticals, Inc. reports positive Phase 2a clinical proof of concept trial results on AVN-211, potent small molecule for treatment of schizophrenia. http://www.avineuro.com/avineuro-pharmaceuticals-inc-reports-positive-phase-2a-clinical-proof-of-concept-trial-results-on-avn-211-potent-small-molecule-for-treatment-of-schizophrenia/ Avineuro Pharmaceuticals hourly 1 https://wordpress.org/?v=4.2.38